GlassScriptPhysician profile
Lori Ann Arnold
NPI 1437169257
$981.61
in general payments reported to CMS, 2019-2025
20 companies · $205 in 2025
The $205 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $216 · 2022: $174 · 2023: $268 · 2024: $120 · 2025: $205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $592.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $592.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $206.23 | 2021-2022 | |
| Abbott Laboratories | $147.29 | 2022-2025 | Cardiomems |
| Hollister Incorporated | $110.48 | 2023 | New Image, Premier |
| Exact Sciences Corporation | $99.90 | 2023-2024 | Cologuard Collection Kit |
| Cycle Pharmaceuticals INC | $46.18 | 2024-2025 | Javygtor |
| Novo Nordisk INC | $42.27 | 2021-2022 | |
| Biomarin Pharmaceutical INC. | $37.79 | 2021-2025 | Palynziq |
| Otsuka America Pharmaceutical, INC. | $34.62 | 2022-2023 | Rexulti |
| Stryker Corporation | $32.16 | 2024 | Procuity |
| Glaxosmithkline, LLC. | $26.65 | 2021-2023 | Shingrix, Bexsero |
| Takeda Pharmaceuticals U.S.A., INC. | $26.64 | 2024 | Vpriv |
| Convatec INC. | $25.30 | 2021 | |
| Orchard Therapeutics North America | $24.61 | 2025 | Lenmeldy |
| Ultragenyx Pharmaceutical INC. | $24.26 | 2023 | |
| Coloplast Corp | $20.69 | 2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $19.10 | 2022 | |
| Idorsia Pharmaceuticals US INC | $18.31 | 2023 | Quviviq |
| Abbvie INC. | $14.85 | 2021 | |
| Tris Pharma INC | $12.67 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Arnold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.